The US regulator will provide verdicts on cancer projects from TG and Athenex, while Sarepta aims for its third Duchenne approval.
October brings US approval decisions for Eysuvis and Brilinta, while a panel meeting sets up a discussion around Covid-19 vaccines.
Poziotinib unexpectedly succeeds in a lung cancer niche, but competition from Takeda must be tracked closely.
The most important clinical readouts of the holiday period concerned Google Health, Axsome, Wave and Spectrum.
By the end of December poziotinib will deliver results that could justify the strategic refocusing Spectrum undertook this year.
Astra’s Caspian study is the star of next week’s World Lung conference, which has also given targeted approaches important supporting roles.
cMet emerges as the latest genetic mutation that could soon see targeted treatments become available.